000304121 001__ 304121
000304121 005__ 20250828114718.0
000304121 0247_ $$2doi$$a10.1021/acs.jmedchem.5c01459
000304121 0247_ $$2pmid$$apmid:40857102
000304121 0247_ $$2ISSN$$a0095-9065
000304121 0247_ $$2ISSN$$a0022-2623
000304121 0247_ $$2ISSN$$a1520-4804
000304121 0247_ $$2ISSN$$a1943-2992
000304121 037__ $$aDKFZ-2025-01784
000304121 041__ $$aEnglish
000304121 082__ $$a610
000304121 1001_ $$00000-0001-7364-1499$$aAmmara, Andrea$$b0
000304121 245__ $$aRepurposing Drug Metabolites into Dual β-Adrenergic Receptor-Carbonic Anhydrase Modulators as Potential Tools for Ocular Disorders.
000304121 260__ $$aWashington, DC$$bACS$$c2025
000304121 3367_ $$2DRIVER$$aarticle
000304121 3367_ $$2DataCite$$aOutput Types/Journal article
000304121 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756368782_18474
000304121 3367_ $$2BibTeX$$aARTICLE
000304121 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304121 3367_ $$00$$2EndNote$$aJournal Article
000304121 500__ $$aepub
000304121 520__ $$aWe report the regioselective chemical derivatization of (R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol, the primary metabolite of the β3-Adrenergic Receptor (β3-AR) agonist mirabegron, with prototypical Carbonic Anhydrase Inhibitors (CAIs) to afford the carbamates 10-14 and the ureido derivatives 15-18. Such compounds were endowed in vitro with distinct inhibition profiles for the human (h) Carbonic Anhydrases (CAs) and showed preferential agonisms for the β3-AR subtype. Among them, 14 induced remarkable intraocular pressure (IOP) lowering in an in vivo transient model of ocular hypertension, with the maximal effect at 120 min post-administration at 1% w/v concentration. Furthermore, the high stability of the compounds in rabbit plasma and their ability to induce full vasodilation in isolated porcine retinal arteries suggested that the observed in vivo effects likely result from a combination of conventional aqueous humor reduction and modulation of ocular vascular tone, both of which are mediated by CAs and β-ARs. The pronounced melanosomal accumulation of representative compounds 14 and 16 highlights their potential as ideal candidates for evaluating pharmacokinetic profiles in ophthalmic applications. The results of this study provide strong evidence for the biomedical repurposing of a neglected metabolite through a novel class of dual-targeting ligands, also offering a promising strategy to help counteract the ongoing decline in drug discovery.
000304121 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000304121 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304121 7001_ $$aCarone, Alessandra$$b1
000304121 7001_ $$aLucarini, Laura$$b2
000304121 7001_ $$aSgambellone, Silvia$$b3
000304121 7001_ $$aMarri, Silvia$$b4
000304121 7001_ $$aVillano, Serafina$$b5
000304121 7001_ $$aMatucci, Rosanna$$b6
000304121 7001_ $$aLuga, Gerta$$b7
000304121 7001_ $$aFittipaldi, Chiara$$b8
000304121 7001_ $$0P:(DE-He78)a8b399fa71eacddc353846ca1d9d2127$$aPecori, Riccardo$$b9$$udkfz
000304121 7001_ $$aPieraccini, Giuseppe$$b10
000304121 7001_ $$aDi Serio, Claudia$$b11
000304121 7001_ $$00000-0001-8137-1513$$aGarcía-Llorca, Andrea$$b12
000304121 7001_ $$aEysteinsson, Thor$$b13
000304121 7001_ $$aKalinin, Stanislav$$b14
000304121 7001_ $$00009-0001-6627-7251$$aViita, Julius Aleksi Olavi$$b15
000304121 7001_ $$aUrtti, Arto$$b16
000304121 7001_ $$00000-0002-1141-6146$$aCarta, Fabrizio$$b17
000304121 7001_ $$aSelleri, Silvia$$b18
000304121 7001_ $$00000-0003-4262-0323$$aSupuran, Claudiu T$$b19
000304121 773__ $$0PERI:(DE-600)1491411-6$$a10.1021/acs.jmedchem.5c01459$$gp. acs.jmedchem.5c01459$$pnn$$tJournal of medicinal chemistry$$vnn$$x0095-9065$$y2025
000304121 909CO $$ooai:inrepo02.dkfz.de:304121$$pVDB
000304121 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8b399fa71eacddc353846ca1d9d2127$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000304121 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000304121 9141_ $$y2025
000304121 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-02$$wger
000304121 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)1200$$2StatID$$aDBCoverage$$bChemical Reactions$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)1210$$2StatID$$aDBCoverage$$bIndex Chemicus$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000304121 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000304121 9201_ $$0I:(DE-He78)D150-20160331$$kD150$$lImmundiversität$$x0
000304121 980__ $$ajournal
000304121 980__ $$aVDB
000304121 980__ $$aI:(DE-He78)D150-20160331
000304121 980__ $$aUNRESTRICTED